Home › Research › Drug development
Unveiling Alzheimer's disease (1901-2025): Historical insights, global burden, biological mechanisms, diagnostics, and therapeutic strategies
Baviskar PS, Mahajan HS.. Ageing research reviews, 2025-12-10
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Alzheimer's disease (AD), first identified by Dr. Alois Alzheimer in 1906, has evolved from a rare presenile dementia to a global health crisis affecting over 58 million people as of 2020, with projections reaching 152 million by 2050. Manuscript offers a comprehensive overview of AD, tracing its historical origins, epidemiological trends, pathophysiological mechanisms, diagnostic advancements, and therapeutic strategies.
What this study adds
Evidence grade: Low
This is a narrative review. This overview describes Alzheimer's disease as a global health crisis affecting over 58 million people as of 2020, with projections reaching 152 million by 2050. It states that the pathogenesis is multifactorial, involving amyloid-β plaque accumulation, tau hyperphosphorylation and other factors.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Baviskar, P. S., & Mahajan, H. S. (2026). Unveiling Alzheimer's disease (1901-2025): Historical insights, global burden, biological mechanisms, diagnostics, and therapeutic strategies. Ageing research reviews. https://doi.org/10.1016/j.arr.2025.102990
Vancouver
Baviskar PS, Mahajan HS. Unveiling Alzheimer's disease (1901-2025): Historical insights, global burden, biological mechanisms, diagnostics, and therapeutic strategies. Ageing research reviews. 2026. doi:10.1016/j.arr.2025.102990. PMID: 41386339.
BibTeX
@article{baviskar2026-41386339,
author = {Baviskar, P. S. and Mahajan, H. S.},
title = {{Unveiling Alzheimer's disease (1901-2025): Historical insights, global burden, biological mechanisms, diagnostics, and therapeutic strategies}},
journal = {Ageing research reviews},
year = {2026},
doi = {10.1016/j.arr.2025.102990},
pmid = {41386339},
url = {https://doi.org/10.1016/j.arr.2025.102990}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Alois Alzheimer in 1906, has evolved from a rare presenile dementia to a global health crisis affecting over 58 million people as of 2020, with projections reaching 152 million by 2050.
- Manuscript offers a comprehensive overview of AD, tracing its historical origins, epidemiological trends, pathophysiological mechanisms, diagnostic advancements, and therapeutic strategies.
- The pathogenesis of AD is multifactorial, involving amyloid-β plaque accumulation, tau protein hyperphosphorylation, cholinergic deficits, oxidative stress, and metal ion dyshomeostasis.
- These mechanisms converge to cause progressive neurodegeneration, cognitive decline, and behavioral disturbances.
Why it matters
This overview describes Alzheimer's disease as a global health crisis affecting over 58 million people as of 2020, with projections reaching 152 million by 2050. It states that the pathogenesis is multifactorial, involving amyloid-β plaque accumulation, tau hyperphosphorylation and other factors.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 42/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on institution's track record, so that was left out: it earned 41 of the 97 points we could judge it on, which is 42 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Ageing research reviews) |
| Journal's citation record | 2 / 4 | Ageing Research Reviews: journal h-index 225 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 3 / 7 | Cited 30 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 15.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 3 / 6 | Cited 5.8× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 2 / 4 | Cited 30 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Hitendra Shaligram Mahajan: h-index 28 (OpenAlex, whole career) |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41386339) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 41 / 97 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 41 of the 97 points we could judge it on is 42 out of 100. |
| Total | 42 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 15.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Drug development from nearby years
Also in Drug development
116 studies in the library are filed under Drug development with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Drug development hub.